Listed by the USPTO as BABIC, CHRISTOPHER M
Tech Center 1700 • Art Units: 1600 1633 1635 1637 1655 1674 1759
This examiner grants 61% of resolved cases
Christopher M. Babic has 386 resolved cases in Art Unit 1600. The allowance rate is 60.6 percent, and the median days to allowance is 1240. The interview lift is 23.6 percent.
Editas Medicine Inc. and The University of Tokyo are the top companies. CHOATE, HALL & STEWART LLP and GREENBLUM & BERNSTEIN, P.L.C. are the top firms.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17412608 | CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | Final Rejection | Editas Medicine, Inc. |
| 18554692 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) PROTEIN | Non-Final OA | Shanghai Argo Biopharmaceutical Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy60.6% of resolved applications examined by Christopher M Babic were allowed (386 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +23.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Christopher M Babic took 1,240 days on average from filing to allowance.
Christopher M Babic examines applications in Art Unit 1600 in Tech Center 1700 (Chemistry & Materials).
